CRISPR / Cas14 (clustered regularly interspaced short palindromic repeats / CRISPR / Cas14) system for detecting mycobacterium tuberculosis complex flora

Through the combination of CRISPR/Cas14 system and fluorescent probe, the problem of difficulty in detecting the Mycobacterium tuberculosis complex in the prior art is solved, and efficient and specific detection of the Mycobacterium tuberculosis complex is achieved, supporting tuberculosis Rapid diagnosis and prevention.

CN119040488APending Publication Date: 2024-11-29ACADEMY OF MILITARY MEDICAL SCIENCES
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202311096159.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-08-29
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing detection technology is difficult to quickly and accurately distinguish and detect the Mycobacterium tuberculosis complex from other mycobacteria, which affects the prevention, control and diagnosis of tuberculosis.

Method used

The CRISPR/Cas14 system is used to combine Cas14 protein, crRNA, tracRNA or sgRNA, and a specific targeting sequence is used to identify the Mycobacterium tuberculosis complex, and fluorescence detection is carried out in combination with a fluorescent probe to establish a fast and accurate detection system.

Benefits of technology

Sensitive and specific detection of the Mycobacterium tuberculosis complex is achieved, and it can determine whether the Mycobacterium tuberculosis complex exists in the sample within 60 minutes, with high detection sensitivity and specificity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004419178230000051
    Figure BDA0004419178230000051
  • Figure BDA0004419178230000061
    Figure BDA0004419178230000061
  • Figure BDA0004419178230000072
    Figure BDA0004419178230000072
Patent Text Reader

Abstract

The invention discloses a CRISPR (clustered regularly interspaced short palindromic repeats) / Cas14 (clustered regularly interspaced short palindromic repeats) system for detecting a mycobacterium tuberculosis The invention provides a CRISPR (clustered regularly interspaced short palindromic repeats) / Cas14 (clustered regularly interspaced short palindromic repeats) system for detecting mycobacterium tuberculosis complex flora, which comprises a Cas14 protein, crRNA (crRNA) and tracRNA (or sgRNA, namely single-chain RNA formed by fusing the crRNA and the tracRNA), or a complex formed by the Cas14 protein, the crRNA and the tracRNA (or the Cas14 protein and the sgRNA); the crRNA comprises a guide sequence of a target sequence of a mycobacterium tuberculosis complex flora; the sequence of the mycobacterium tuberculosis complex flora target spot is shown as SEQ ID No.1. The invention also discloses a method for preparing the mycobacterium tuberculosis complex flora target spot. The CRISPR / Cas14 system provided by the invention can be used for sensitively and specifically distinguishing mycobacterium tuberculosis complex strains from other mycobacteria. The method is of great significance to rapid and accurate identification of mycobacterium tuberculosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a CRISPR / Cas14 system for detecting a complex flora of Mycobacterium tuberculosis. Background Art

[0002] Tuberculosis is a disease caused by Mycobacterium tuberculosis that seriously threatens human health. According to the 2021 WHO tuberculosis report, one-quarter of the world's population, about 2 billion people, are infected with Mycobacterium tuberculosis. my country is the second largest country in the world with a high burden of tuberculosis. Rapid and accurate detection of Mycobacterium tuberculosis is crucial for tuberculosis prevention and control. Mycobacterium tuberculosis complex is the main pathogen that causes tuberculosis in humans and animals, including Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium africanum, Mycobacterium voles, Mycobacterium caprae, and Mycobacterium sealis.

[0003] The gene encoding the small ribosomal subunit (16S rRNA) is highly conserved, with only one or several nucleotide changes at certain positions in the variable region. The 16S rDNA variable region can be used to distinguish the Mycobacterium tuberculosis complex from other mycobacteria. Summary of the invention

[0004] The object of the present invention is to provide a CRISPR / Cas14 system for detecting a complex flora of Mycobacterium tuberculosis.

[0005] In a first aspect, the present invention claims a CRISPR / Cas14 system for detecting Mycobacterium tuberculosis complex.

[0006] The CRISPR / Cas14 system for detecting the Mycobacterium tuberculosis complex claimed in the present invention may include the following (A1) or (A2):

[0007] (A1) Cas14 protein, crRNA and tracRNA, or a complex formed by the three; the crRNA includes a guide sequence targeting a target sequence of the Mycobacterium tuberculosis complex; the Mycobacterium tuberculosis complex target sequence is shown in SEQ ID No. 1;

[0008] (A2) Cas14 protein, sgRNA, or a complex formed by the two; the sgRNA is a single-stranded RNA formed by the fusion of the crRNA and the tracRNA.

[0009] Furthermore, the guide sequence is shown as positions 206-226 of SEQ ID No.2.

[0010] In a specific embodiment of the present invention, the sequence of the sgRNA is shown as SEQ ID No.2.

[0011] In a specific embodiment of the present invention, the Cas14 protein is a Cas14a protein.

[0012] In a second aspect, the present invention claims a kit for detecting the Mycobacterium tuberculosis complex.

[0013] The kit for detecting the Mycobacterium tuberculosis complex claimed in the present invention may include the CRISPR / Cas14 system described in the first aspect above.

[0014] Furthermore, the kit may also include a primer pair for specific amplification of mycobacteria; the primer pair consists of two single-stranded DNAs shown in SEQ ID No.3 and SEQ ID No.4.

[0015] Furthermore, the kit may also include a positive substrate and / or a negative substrate; the positive substrate is the single-stranded DNA shown in SEQ ID No.5; the negative substrate is the single-stranded DNA shown in SEQ ID No.6.

[0016] Furthermore, the kit may also include a fluorescent probe; the fluorescent probe is a single-stranded DNA shown in SEQ ID No. 7, and has a FAM fluorescent group and a BHQ1 quenching group at both ends respectively.

[0017] In a third aspect, the present invention claims protection for any of the following substances:

[0018] (B1) the crRNA described in the first aspect above;

[0019] (B2) the sgRNA described in the first aspect above;

[0020] (B3) The primer pair described in the second aspect above.

[0021] In a fourth aspect, the present invention claims a method for detecting the Mycobacterium tuberculosis complex.

[0022] The method for detecting the complex flora of Mycobacterium tuberculosis claimed in the present invention may include the following steps:

[0023] (C1) extracting genomic DNA from the sample to be tested, using it as a template, and performing asymmetric PCR amplification using the primer pair described in the second aspect above to obtain a single-stranded DNA fragment of the target nucleic acid;

[0024] (C2) preparing a CRISPR-Cas14 detection system containing the following components: the target nucleic acid single-stranded DNA fragment, the Cas14 protein described in the first aspect above, the crRNA and tracRNA described in the first aspect above or the sgRNA described in the first aspect above, and the fluorescent probe described in the second aspect above;

[0025] (C3) detecting the fluorescence intensity of the CRISPR-Cas14 detection system, and determining whether the sample to be tested contains a complex flora of Mycobacterium tuberculosis based on the fluorescence intensity.

[0026] The result determination method can be as follows: if the fluorescence value at 60 minutes of detection is greater than the sum of the signal mean and 3 times the standard deviation of the negative sample (such as using a negative substrate, i.e., the single-stranded DNA shown in SEQ ID No. 6), it is determined to be positive, i.e., the detected sample contains a complex flora of Mycobacterium tuberculosis.

[0027] Furthermore, in step (C1), when the asymmetric PCR is performed, the molar concentration of the primer shown in SEQ ID No. 4 is 10 times that of the primer shown in SEQ ID No. 3.

[0028] Furthermore, in step (C2), the CRISPR-Cas14 detection system also contains 10×CutSmart.

[0029] Further, in step (C3), the fluorescence intensity of the CRISPR-Cas14 detection system is detected by selecting an excitation wavelength of 490 nm and an emission wavelength of 520 nm, setting the detection temperature to 45° C., and reading the plate once every 1 min for a total time of 2 h.

[0030] The sample to be tested may be a complex flora of Mycobacterium tuberculosis (such as Mycobacterium tuberculosis) or other mycobacteria.

[0031] In a specific embodiment of the present invention, the sample to be tested is specifically selected from the following: Mycobacterium tuberculosis, Mycobacterium shinjuku, Mycobacterium schrenkieri, Mycobacterium terrestris, Mycobacterium phlei, Mycobacterium fortuitum, Mycobacterium abscessus, Mycobacterium chelonae, Mycobacterium gordonii, Mycobacterium scrofula, Mycobacterium asiatica, Mycobacterium kansasii, and Mycobacterium avium.

[0032] The method for detecting the complex flora of Mycobacterium tuberculosis provided by the present invention can be a non-disease diagnosis and treatment method or a disease diagnosis and treatment method. The non-disease diagnosis and treatment method, for example, detects whether and how much complex flora of Mycobacterium tuberculosis is contained in cells before and after the use of the drug when screening tuberculosis prevention and treatment drugs at the cell level.

[0033] In a fifth aspect, the present invention claims protection for any of the following applications:

[0034] (D1) Use of the CRISPR / Cas14 system described in the first aspect above, or the kit described in the second aspect above, or the substance described in the third aspect above in detecting a complex flora of Mycobacterium tuberculosis or in preparing a product for detecting a complex flora of Mycobacterium tuberculosis.

[0035] (D2) Use of the CRISPR / Cas14 system described in the first aspect above, or the kit described in the second aspect above, or the substance described in the third aspect above in distinguishing the Mycobacterium tuberculosis complex from other mycobacteria or in preparing a product for distinguishing the Mycobacterium tuberculosis complex from other mycobacteria.

[0036] (D3) Use of the CRISPR / Cas14 system described in the first aspect above, or the kit described in the second aspect above, or the substance described in the third aspect above, or the method described in the fourth aspect above in screening tuberculosis drugs or preparing products for screening tuberculosis drugs.

[0037] (D4) Use of the CRISPR / Cas14 system described in the first aspect above, or the kit described in the second aspect above, or the substance described in the third aspect above, or the method described in the fourth aspect above in evaluating the efficacy of tuberculosis drugs or in preparing a product for evaluating the efficacy of tuberculosis drugs.

[0038] The present invention compares the 16S rDNA of more than 80 strains of mycobacteria downloaded from the NCBI gene library, designs a sequence specific to the complex flora of Mycobacterium tuberculosis, and establishes a Cas14 nucleic acid detection system for the complex flora of Mycobacterium tuberculosis by utilizing the characteristics of the CRISPR / Cas14 nucleic acid detection system with single-base mismatch recognition ability. The results show that the system can sensitively and specifically distinguish Mycobacterium tuberculosis complex strains from other mycobacteria. The present invention is of great significance for the rapid and accurate detection of Mycobacterium tuberculosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 Colony PCR identification results for Mtb-sgRNA vector construction.

[0040] Figure 2 The electrophoresis results of the transcription template PCR product (A) and the transcription product (B). 1 is the sample, and 2 is the negative control with water as the template.

[0041] Figure 3The Cas14 detection system Mtb-sgRNA distinguishes Mycobacterium tuberculosis from other Mycobacterium species in the complex flora of non-tuberculous Mycobacteria. A shows the results of detecting the synthesis of single-stranded Mtb16s145 and Msj16s145 from 16S rDNA fragments of Mycobacterium tuberculosis and Mycobacterium shinjukuensis; B shows the results of detecting Mycobacterium tuberculosis and other Mycobacterium species in the complex flora of 11 non-tuberculous Mycobacteria.

[0042] Figure 4 Sensitivity experiment of Cas14 detection system for detecting Mycobacterium tuberculosis. DETAILED DESCRIPTION

[0043] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.

[0044] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.

[0045] Example 1. Establishment and application of the CRISPR / Cas14 system for detecting complex flora of Mycobacterium tuberculosis

[0046] 1. Experimental Materials

[0047] pLBH531_MBP-Cas14a1 expression plasmid was purchased from Addgene (ID: 112500); DH5α Escherichia coli competent cells were purchased from Beijing Qingke Biotechnology Co., Ltd., and oligonucleotide forward and reverse strands and PCR amplification primers were synthesized by Beijing Qingke Biotechnology Co., Ltd.; pSMART plasmid was purchased from Tianyi Huiyuan Biotechnology Co., Ltd.; BCA protein quantification kit and TranscriptAid T7 High Yield Transcription Kit were purchased from Thermo Scientific; TEV enzyme, BbsI endonuclease, T4 ligase, and 10× Cutsmart buffer were purchased from NEB, USA; PCR MIX was purchased from Beijing Qingke Biotechnology Co., Ltd.; QIAquick RCR Purification Kit and QIAprep Spin Miniprep Kit were purchased from Qiagen, Germany. The main instruments include PCR instrument (T100TM Thermal Cycler, BIO-RAD), SpectraMax M2 (Molecular Devices), full temperature shaking incubator (Shanghai Peiying Experimental Instrument Co., Ltd.), constant temperature incubator (Tianjin Test Instrument Co., Ltd.), NanoDrop 2000 (Thermo Fisher). The fluorescent probe is a single-stranded DNA composed of 12 synthetic T bases, with FAM fluorescent group and BHQ1 quenching group at both ends.

[0048] 2. Experimental Methods

[0049] 1. Acquisition of Cas14a protein

[0050] The pLBH531_MBP-Cas14a1 expression plasmid was transformed into BL21(DE3) competent cells by chemical transformation. Monoclonal colonies with good protein expression were selected and inoculated into liquid LB medium containing ampicillin antibiotics. Cultured at 37℃200rpm until OD 600=0.8, add IPTG to a final concentration of 0.5mM, and induce expression for 16h. After induction, collect the bacteria by centrifugation. Wash the bacteria twice with an appropriate volume of PBS. Resuspend the bacteria with Lysis Buffer, add protease inhibitors and ultrasonically lyse in an ice bath for 30min, centrifuge for 15min, and collect the supernatant. Filter with a 0.22μm filter, add to a nickel column equilibrated with Lysis Buffer, and incubate at 4℃ for 1h. Then wash the nickel column with Wash buffer I, Wash buffer II, and Wash buffer III respectively. For the components of various buffers, see the instructions of the nickel column affinity chromatography kit. Finally, elute the target protein with Elution buffer, collect 0.5ml in each tube, and measure OD 280 , and combine the proteins with a concentration greater than 1.0 mg / mL. Prepare the enzyme digestion system according to Table 1. After overnight digestion at 4°C, hang the nickel column to remove the MBP-tagged protein. Collect the protein after hanging the column and measure the protein concentration using the BCA protein detection kit. Aliquot the protein and freeze it at -80°C.

[0051] Table 1. TEV enzyme digestion system

[0052]

[0053] 2. sgRNA transcription template design

[0054] More than 80 16S rDNA sequences of Mycobacterium bacteria were downloaded from the NCBI database for comparison and analysis, and the 21bp sequence specific to the complex mycobacterium was selected as the target sequence, as follows:

[0055] 5'-ACCGCTAAAGCGCTTTCCACC-3' (SEQ ID No. 1).

[0056] Based on this, the Mtb-Oligo-F / R sequence was designed, as shown in Table 2.

[0057] Table 2. Mtb-Oligo-F / R sequence

[0058] name Sequence (5'-3') Mtb-Oligo-F CAACGGTGGAAAGCGCTTTAGCGGT Mtb-Oligo-R AAACACCGCTAAAGCGCTTTCCACC

[0059] 3. Construction of plasmid corresponding to sgRNA transcription template

[0060] The T7 promoter and the coding DNA sequence of tracRNA were directly connected head to tail and inserted between the two restriction sites of BamHI and EcoRI of the pSMART vector. Among them, the T7 promoter sequence: TAATACGACTCACTATAGG G (20bp), the tracrRNA sequence: CUUCACUGAUAAAGUGGAGAACCGCUUCACCAAA AGCUGUCCCUUAGG GGAUUAGAACUUGAGUGAAGGUGGGCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUCUUCGGAAAGUAAC CCUCGAAACAAAUUCAUUUUUCCUCUCCAAUUCUGCACAAGAAAGUUGCAGAACCCGAA UAGACGAAUGAAG GAAUGCAAC (202bp). Then, two BbSI restriction sites were inserted after the tracrRNA sequence, and the modified plasmid was obtained after sequencing verification, which was named pSMART-1. Two complementary oligonucleotide chains were synthesized, named Mtb-Oligo-F and Mtb-Oligo-R, and the sequences are shown in Table 2. The annealing system was prepared according to Table 3, 95℃5min, 56℃ annealing for 15min. The annealed double-stranded DNA was added to the connection system according to Table 4 and placed on the PCR instrument for reaction. The reaction conditions were 37℃5min, 25℃5min, 10 cycles: then 37℃30min, 65℃5min.

[0061] Table 3. Oligonucleotide annealing system

[0062] Components Dosage 100 μM Mtb-Oligo-F 9μL 100 μM Mtb-Oligo-R 9μL 10×TE buffer 2μL Total volume 20μl

[0063] Table 4. Ligation reaction system

[0064] Components Dosage 10×T4 Ligation Buffer 2μL Annealing product 1μL pSMART-1 Plasmid 100ng BbsI endonuclease 1μL T4 Ligase 1μL Enzyme-free water Make up to 20 μL Total volume 20μL

[0065] 4. Obtaining the plasmid corresponding to the Mtb-sgRNA transcription template

[0066] Add the ligation product obtained in step 3 to the DH5α competent cells in the ice bath and mix thoroughly. After ice bathing for 30 minutes, heat shock at 42°C for 90 seconds and let stand on ice for 5 minutes. Add 800μL liquid LB medium and incubate at 200rpm at 37°C for 1 hour. Take an appropriate amount of bacterial solution and spread it on the kanamycin-resistant LB plate, invert it in a 37°C constant temperature incubator and culture it overnight. Pick the monoclonal colonies grown on the solid plate and streak them. After the colonies grow, pick some colonies with a gun tip and resuspend them in 50μL ultrapure water. After heating at 99°C for 10 minutes, centrifuge at 1200rpm for 3 minutes and take 3μL of supernatant as a template for colony PCR identification.

[0067] The upstream and downstream primer sequences for colony PCR amplification are:

[0068] Mtb-F: 5'-CCCCCCGTTCAGCCCGACCG-3';

[0069] Mtb-R: 5'-ACCGCTAAAGCGCTTTCCACCGTTG-3'.

[0070] The colony PCR amplification system is shown in Table 5. The amplification conditions are 98°C for 2 min; 98°C for 10 s, annealing at 62°C for 10 s, extension at 72°C for 10 s, 35 cycles; 72°C for 5 min.

[0071] Table 5. PCR amplification system for positive colony identification

[0072]

[0073]

[0074] After amplification, 10 μL was taken for agarose gel electrophoresis, and the monoclonal colonies that amplified the target band were selected for sequencing, and the colonies with correct sequencing results were selected for subsequent experiments.

[0075] 5. Mtb-sgRNA transcription and purification

[0076] Take 100 μL of the preserved bacterial solution and inoculate it into 5 mL of kanamycin-resistant liquid LB medium and culture it until OD 600 = about 1.0, centrifuge to collect bacteria, and extract plasmids using a plasmid extraction kit. Use the purified plasmid as a template and use primers for Mtb-F / R (see above for specific sequences) for PCR amplification. The amplification system and conditions are the same as those for colony identification PCR in step 4.

[0077] The amplified product was purified using a PCR product kit, and the purified PCR product was used as a template for in vitro transcription according to the instructions of the TranscriptAid T7 High Yield Transcription Kit. The transcription product was purified using an RNA purification kit and electrophoresed in a 1% agarose gel for 30 minutes, and the concentration of the obtained sgRNA was detected using NanoDrop2000.

[0078] 6. Synthesis and amplification of detection targets

[0079] Sequence comparison analysis found that the 16S rDNA of Mycobacterium shinjukuense was most similar to the 16S rDNA sequence of the Mycobacterium tuberculosis complex, so it was used as a negative control representative strain to establish the detection method. According to the 16S rDNA sequences of Mycobacterium tuberculosis and Mycobacterium shinjukuense in the NCBI database, a 145bp sequence containing the target sequence shown in SEQ ID No.1 was intercepted and handed over to the company for single-strand synthesis, as shown in Table 6, as the positive and negative control substrates of the detection system.

[0080] Table 6. 145 bp substrate sequences of Mycobacterium tuberculosis and Mycobacterium shinjukuensis

[0081]

[0082] 200 bp sequences of Mycobacterium tuberculosis and the corresponding Mycobacterium shinjukuensis 16SrDNA containing the target sequence shown in SEQ ID No. 1 were intercepted and named Mtb-16sFrag and Msj-16sFrag, respectively, as shown in Table 7. The two sequences were inserted into the EcoRI and HindIII restriction sites of the pUC19 plasmid, respectively, to construct the recombinant plasmids pUC19-Mtb16sFrag and pUC19-Msj16sFra.

[0083] Description of the structure of the recombinant plasmid pUC19-Mtb16sFrag: The recombinant plasmid was obtained by cloning the Mtb-16sFrag sequence (see Table 7) between the restriction sites EcoRI and HindIII of the pUC19 plasmid.

[0084] Structural description of the recombinant plasmid pUC19-Msj16sFrag: The recombinant plasmid was obtained by cloning the Msj-16sFrag sequence (see Table 7) between the restriction sites EcoRI and HindIII of the pUC19 plasmid.

[0085] Table 7. 16S rDNA 200bp fragment sequences of Mycobacterium tuberculosis and Mycobacterium shinjukuensis

[0086]

[0087] The above two recombinant plasmids were used as templates, 16SrDNA-F: 5'-CTGCACTTCGGGATAAGCCT-3' (SEQ ID No. 3); 16SrDNA-R: 5'-CCGTATCTCAGTCCCAGTGT-3' (SEQ ID No. 4) were used as primers, and the asymmetric PCR system was prepared according to Table 8. The amplification conditions were 98°C for 2 min; 98°C for 10 s, annealing at 58°C for 10 s, extension at 72°C for 10 s, 50 cycles; 72°C for 5 min. The product was single-stranded DNA.

[0088] Table 8. Asymmetric PCR amplification system

[0089] Components Dosage template 1μL 1μM 16srDNA-F 5μL 10μM 16srDNA-R 5μL PCR MIX 39μL Total volume 50μL

[0090] 7. Detection of Mycobacterium tuberculosis by Cas14 detection system

[0091] The composition of the Cas14 nucleic acid detection system is shown in Table 9. After adding the various components required for the detection system to the 96-well all-black detection plate in turn, put it into the SpectraMax M2 enzyme label detector, select 490nm excitation wavelength and 520nm emission wavelength, set the detection temperature to 45°C, read the plate once every 1min, and the total time is 2h.

[0092] Table 9. Cas14 detection system

[0093]

[0094]

[0095] Wherein, the fluorescent probe is specifically as follows:

[0096] 5'FAM-TTTTTTTTTTTT-3'BHQ1 (SEQ ID No. 7).

[0097] Result determination: If the fluorescence value at 60 minutes of detection is greater than the sum of the signal mean and 3 times the standard deviation of the negative sample (such as using a negative substrate, i.e., the single-stranded DNA shown in SEQ ID No. 6), it is determined to be positive, that is, the detected sample contains a complex flora of Mycobacterium tuberculosis.

[0098] 8. Evaluation of the sensitivity and specificity of Cas14 detection system for detecting Mycobacterium tuberculosis

[0099] (1) Sensitivity test

[0100] The genomic DNA of the Mycobacterium tuberculosis standard strain H37Rv was serially diluted to a concentration of 10 -1 ,10 -2 ,10 -3 ,10 -4,10 -5 ng / μL, using gradient diluted genomic DNA as template, using 16SrDNA-F: 5'-CTGCACTTCGGGATAAGCCT-3' (SEQ ID No.3); 16SrDNA-R: 5'-CCGTATCTCAGTCCCAGTG T-3' (SEQ ID No.4) as primers, asymmetric PCR amplification was performed (for specific operations, see above). According to Table 9, the amplified product was added to the detection system for detection and sensitivity test was performed.

[0101] (2) Specificity detection

[0102] The genomic DNA of the standard strain of Mycobacterium tuberculosis H37Rv and 11 other Mycobacterium strains that do not belong to the Mycobacterium tuberculosis complex (Mycobacterium tuberculosis, Mycobacterium Shinjuku, Mycobacterium schrenckii, Mycobacterium terrestris, Mycobacterium phlei, Mycobacterium fortuitum, Mycobacterium abscessus, Mycobacterium chelonae, Mycobacterium gordonii, Mycobacterium scrofula, Mycobacterium asiatica, Mycobacterium kansasii, and Mycobacterium avium) with a concentration of 1 ng / μL were added to the test body for detection to evaluate the specificity of the detection. The above strains are all recorded in the article "Yong Zhao, et al. Locked Nucleic Acid Probe-Based Real-Time PCR Assay for the Rapid Detection of Rifampin-Resistant Mycobacterium tuberculosis. PLOS ONE|DOI:10.1371 / journal.pone.0143444November24,2015", which can be obtained by the public from the applicant and can only be used to repeat the experiments of the present invention and cannot be used for other purposes.

[0103] 3. Results and Analysis

[0104] 1. Obtaining Mtb-sgRNA

[0105] The double-stranded fragments formed by annealing Mtb-Oligo-F and Mtb-Oligo-R (Table 2) were cloned into the pSMART-1 vector. After the colonies grew, the primers Mtb-F and Mtb-R (sequences are shown in step 2.4 above) were used for colony PCR identification. The results showed that the size of the fragments amplified by single clones 1, 5, 7, 9, and 10 was consistent with the theoretical length of 706 bp. Figure 1Two monoclonal colonies were selected to extract plasmids for sequencing. The sequencing results showed that the crRNA target gene fragment (guide sequence) for binding to the target sequence shown in SEQ ID No. 1 had been inserted into the pSMART-1 plasmid without point mutation. The recombinant plasmid was named pSMART-Probe.

[0106] The structure of the recombinant plasmid pSMART-Probe is described as follows: the DNA fragment formed by annealing Mtb-Oligo-F and Mtb-Oligo-R (Table 2) is cloned between two BbsI restriction sites of the pSMART-1 vector to obtain the recombinant plasmid.

[0107] 2. Mtb-sgRNA transcription

[0108] The extracted pSMART-Probe plasmid was used as a template and the primers Mtb-F and Mtb-R (sequences are shown in step 2.4 above) were used for PCR amplification. After completion of amplification, the expected length of the amplified product was 706 bp. After agarose gel electrophoresis, a bright band was visible between 500-750 bp. The band size was in line with expectations. Figure 2 A. Purify the PCR product and use it as a template for transcription. The transcription results are shown in Figure 2 Middle B.

[0109] The sequence of the Mtb-sgRNA finally transcribed is shown in SEQ ID No. 2. Among them, positions 206-226 of SEQ ID No. 2 are guide sequences.

[0110] 3. Detection of Mycobacterium tuberculosis by Cas14 system and specificity evaluation

[0111] According to the specific detection method in step 2, the synthesized Mycobacterium tuberculosis and Mycobacterium nijuku single-stranded substrates (SEQ ID No. 5 and SEQ ID No. 6) were added to the Cas14 detection system for detection, and three replicates were performed for each sample. The results showed that the Cas14 detection system had a good ability to distinguish the synthesized Mycobacterium tuberculosis and Mycobacterium nijuku 16SrDNA single strands. Figure 3 Middle A.

[0112] Using the genomic DNA of Mycobacterium tuberculosis and 11 non-tuberculous mycobacteria as templates, asymmetric PCR was used to amplify the target nucleic acid single-stranded DNA fragments, which were then added to the Cas14 detection system for detection. The fluorescence signal value at a detection time of 60 min was plotted. Figure 3 The results showed that the detection system can distinguish Mycobacterium tuberculosis from other mycobacteria in the non-tuberculosis mycobacterium complex.

[0113] 4. Sensitivity of Cas14 system in detecting Mycobacterium tuberculosis

[0114] According to the sensitivity detection method in step 2, the synthesized Mtb16s-145 single-stranded substrate (SEQ ID No. 5) and the asymmetric PCR amplification product using the genomic DNA of the standard strain of Mycobacterium tuberculosis H37Rv at a series of concentrations as a template were added to the detection system for detection. The results showed that the sensitivity could reach 10 -3 Up to 10 -4 ng / μL, such as Figure 4 .

[0115] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.

Claims

1. A CRISPR / Cas14 system for detecting a complex flora of Mycobacterium tuberculosis, comprising the following (A1) or (A2): (A1) Cas14 protein, crRNA and tracRNA, or a complex formed by the three; the crRNA includes a guide sequence targeting a target sequence of the Mycobacterium tuberculosis complex; the Mycobacterium tuberculosis complex target sequence is shown in SEQ ID No. 1; (A2) Cas14 protein, sgRNA, or a complex formed by the two; the sgRNA is a single-stranded RNA formed by the fusion of the crRNA and the tracRNA.

2. The CRISPR / Cas14 system according to claim 1, characterized in that: The guide sequence is shown in positions 206-226 of SEQ ID No. 2; Furthermore, the sequence of the sgRNA is shown in SEQ ID No.

2.

3. The CRISPR / Cas14 system according to claim 1 or 2, characterized in that: The Cas14 protein is a Cas14a protein.

4. A kit for detecting a complex flora of Mycobacterium tuberculosis, comprising the CRISPR / Cas14 system described in any one of claims 1 to 3.

5. The kit according to claim 4, characterized in that: The kit also includes a primer pair for specific amplification of mycobacteria; the primer pair consists of two single-stranded DNAs shown in SEQ ID No.3 and SEQ ID No.

4.

6. The kit according to claim 4 or 5, characterized in that: The kit further comprises a positive substrate and / or a negative substrate; the positive substrate is the single-stranded DNA shown in SEQ ID No.5; the negative substrate is the single-stranded DNA shown in SEQ ID No.

6.

7. A kit according to any one of claims 4 to 6, characterized in that: The kit also includes a fluorescent probe; the fluorescent probe is a single-stranded DNA shown in SEQ ID No. 7, and has a FAM fluorescent group and a BHQ1 quenching group at both ends.

8. Any of the following substances: (B1) the crRNA according to any one of claims 1 to 3; (B2) the sgRNA according to any one of claims 1 to 3; (B3) The primer pair described in claim 5.

9. A method for detecting a complex flora of Mycobacterium tuberculosis, comprising the following steps: (C1) extracting genomic DNA from the sample to be tested, using it as a template, and performing asymmetric PCR amplification using the primer pair described in claim 5 to obtain a single-stranded DNA fragment of the target nucleic acid; (C2) preparing a CRISPR-Cas14 detection system comprising the following components: the target nucleic acid single-stranded DNA fragment, the Cas14 protein described in any one of claims 1 to 3, the crRNA and tracRNA described in any one of claims 1 to 3 or the sgRNA described in any one of claims 1 to 3, and the fluorescent probe described in claim 7; (C3) detecting the fluorescence intensity of the CRISPR-Cas14 detection system, and determining whether the sample to be tested contains a complex flora of Mycobacterium tuberculosis based on the fluorescence intensity.

10. Any of the following applications: (D1) Use of the CRISPR / Cas14 system of any one of claims 1 to 3, the kit of any one of claims 4 to 7, or the substance of claim 8 in detecting a Mycobacterium tuberculosis complex or in preparing a product for detecting a Mycobacterium tuberculosis complex; (D2) Use of the CRISPR / Cas14 system of any one of claims 1 to 3, the kit of any one of claims 4 to 7, or the substance of claim 8 in distinguishing the Mycobacterium tuberculosis complex from other mycobacteria or in preparing a product for distinguishing the Mycobacterium tuberculosis complex from other mycobacteria; (D3) Use of the CRISPR / Cas14 system of any one of claims 1 to 3, the kit of any one of claims 4 to 7, the substance of claim 8, or the method of claim 9 in screening tuberculosis drugs or in preparing a product for screening tuberculosis drugs; (D4) Use of the CRISPR / Cas14 system described in any one of claims 1 to 3, or the kit described in any one of claims 4 to 7, or the substance described in claim 8, or the method described in claim 9 in evaluating the efficacy of tuberculosis drugs or in preparing a product for evaluating the efficacy of tuberculosis drugs.

Citation Information

Cited By

  • Method for detecting geminivirus in tomato plant and bemisia tabaci based on aMIRA-CRISPR / Cas14a system

    CN120924720A